These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29311482)

  • 1. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
    Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
    Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
    Fukudo M; Ikemi Y; Togashi Y; Masago K; Kim YH; Mio T; Terada T; Teramukai S; Mishima M; Inui K; Katsura T
    Clin Pharmacokinet; 2013 Jul; 52(7):593-609. PubMed ID: 23532985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
    Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
    Arbitrio M; Di Martino MT; Barbieri V; Agapito G; Guzzi PH; Botta C; Iuliano E; Scionti F; Altomare E; Codispoti S; Conforti S; Cannataro M; Tassone P; Tagliaferri P
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):205-9. PubMed ID: 26607259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
    Kobayashi H; Sato K; Niioka T; Miura H; Ito H; Miura M
    Clin Lung Cancer; 2015 Jul; 16(4):274-81. PubMed ID: 25554506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
    Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
    J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
    Evelina Cardoso ; Guidi M; Khoudour N; Pascaline Boudou-Rouquette ; Fabre E; Tlemsani C; Arrondeau J; François Goldwasser ; Vidal M; Schneider MP; Wagner AD; Widmer N; Blanchet B; Csajka C
    Clin Ther; 2020 Jul; 42(7):1302-1316. PubMed ID: 32631634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.
    Thomas F; Rochaix P; White-Koning M; Hennebelle I; Sarini J; Benlyazid A; Malard L; Lefebvre JL; Chatelut E; Delord JP
    Eur J Cancer; 2009 Sep; 45(13):2316-23. PubMed ID: 19523815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
    Hamada A; Sasaki J; Saeki S; Iwamoto N; Inaba M; Ushijima S; Urata M; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Kai Y; Isobe T; Kohrogi H; Saito H
    Pharmacogenomics; 2012 Apr; 13(5):615-24. PubMed ID: 22462752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
    Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
    Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
    Ma Y; Xin S; Huang M; Yang Y; Zhu C; Zhao H; Zhang Y; Chen L; Zhao Y; Li J; Zhuang W; Zhu X; Zhang L; Wang X
    Pharmacogenomics J; 2017 Jul; 17(4):325-330. PubMed ID: 27089937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
    Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
    BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
    Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
    Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Emoto-Yamamoto Y; Iida S; Kawanishi T; Fukuoka M
    J Clin Pharm Ther; 2015 Apr; 40(2):232-9. PubMed ID: 25402940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic Variants in the
    Morau MV; Seguin CS; Visacri MB; Pincinato EC; Moriel P
    Genes (Basel); 2024 May; 15(5):. PubMed ID: 38790220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
    Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
    Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
    Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
    Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.